Experimental causal and symptomatic therapies for the treatment of ALS
Project management at the University of Würzburg:
The intrathecally administration of BDNF in patients with ALS was tested within a phase I/II study. Outcome parameters were the optimal doses and the tolerability of the continuous intrathecal application of the neurotrophic factor. The application method as well as the agent was proven as well tolerable. Thus, BDNF could be used in a consecutive phase III effectivity study in ALS.
The use of Clenbuterol as symptomatic treatment for strengthening of the muscle force in ALS could not be confirmed in a study on the literature of this topic.
Injections of botulinum toxin into the salivary glands in ALS were proven to be safe and effective as significant reduction of the sialorrhea could be shown by using clinical parameters and a scintigraphic method.
Projekt period: from 08.1996 to 02.2001
Wirtschaftsunternehmen ( (Amgen, Medtronic) ) ,Granting date: 22.08.1996